Anzeige
Mehr »
Donnerstag, 08.05.2025 - Börsentäglich über 12.000 News
4 Kilometer-Bohrlöcher in Folge - und der Markt schläft noch?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
324 Leser
Artikel bewerten:
(2)

Single Cell Analysis Market worth US$7.56 billion by 2030 with 14.7% CAGR | MarketsandMarkets

Finanznachrichten News

DELRAY BEACH, Fla., May 7, 2025 /PRNewswire/ -- The global Single Cell Analysis Market , valued at US$3.55 billion in 2024, is forecasted to grow at a robust CAGR of 14.7%, reaching US$3.81 billion in 2025 and an impressive US$7.56 billion by 2030. Growth in this market can be attributed to factors such as the rising incidence of cancer and immunological disorders, technological developments in single-cell analysis products, the growing focus on the advancement of stem cell research, and the increasing focus on the biotechnology sector. However, the high cost of single-cell analysis products may hamper the growth of the market.

MarketsandMarkets Logo

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171955254

Browse in-depth TOC on "Single Cell Analysis Market"

721 - Tables
66 - Figures
517 - Pages

By Based on product, the single-cell analysis market is segmented into consumables and instruments. The consumables segment is further divided into reagents, assay kits, beads, microplates, and other consumables. The instruments segment is further segmented into next-generation sequencing, microscopy, flow cytometry, polymerase chain reaction, mass spectrometry, and other instruments. The consumables segment dominated the market in 2024 and is expected to continue to dominate the market during the forecast period. The large share of this segment can be attributed to the increasing demand for high-quality reagents to ensure reliable and reproducible results. Additionally, the growing focus on the development of advanced cellular therapies is anticipated to promote segmental growth.

By end users, the single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centres. The academic & research laboratories segment is estimated to register the highest growth rate during the forecast period. The increasing emphasis on developing cell-based therapeutics, driven by the rising incidence of cancer, is anticipated to propel growth in this segment. Moreover, the surge in investments and funding for life science research has led to a greater adoption of advanced technologies, such as single-cell analysis, further enhancing the segment's growth in the market.

By geography, the single-cell analysis market is segmented into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific is anticipated to register the highest growth in the single-cell analysis market owing to the increasing focus on the development of cell-based therapies, high government investments & funding for R&D, and the booming healthcare sector. In addition, the emphasis on modernizing healthcare infrastructure and the increasing adoption of advanced technologies for research and clinical applications are expected to drive the growth of single-cell analysis in the Asia Pacific region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=171955254

The key players in the single-cell analysis market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), BD (US), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), 10x Genomics (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), DiaSorin S.p.A. (Italy), Standard BioTools (US), Tecan Trading AG (Switzerland), Sartorius AG (Germany), Corning Incorporated (US), Cytek Biosciences (US), Takara Bio Inc. (Japan), bioMérieux (France), Revvity (US), Bio-Techne (US), PacBio (US), Bruker (US), Promega Corporation (US), Oxford Nanopore Technologies Plc (UK), The Menarini Group (Italy), Singleron Biotechnologies (Germany), BICO (Sweden), Fluent BioSciences (US), RareCyte, Inc. (US), Cell Microsystems (US), NanoCellect Biomedical (US), Apogee Flow Systems Ltd. (UK), Creative Biolabs (US), Sphere Bio (UK), and Yokogawa Electric Corporation (Japan), among others.

BD (US):

BD (Becton, Dickinson, and Company) develops, manufactures, and distributes medical instruments and reagents. The company's products are used in various applications, including biosciences, diabetes care, respiratory disorder management, and diagnostic and analytical applications. BD operates in over 50 countries across Europe, Latin America, the Asia Pacific, and North America. The company is also committed to developing innovative products. For example, in February 2023, BD launched a new instrument for single-cell multiomics analysis, which allows scientists to conduct high-throughput studies without compromising sample integrity. This advancement has the potential to accelerate discovery across a wide range of fields, including immunology, genetic disease research, cancer, and chronic disease research.

THERMO FISHER SCIENTIFIC INC. (US):

Thermo Fisher is a leading company in science and technology, specializing in manufacturing high-end analytical instruments, laboratory equipment, software, consumables, reagents, and services for scientific research, analysis, discovery, and diagnostics. The company operates in over 180 countries across North America, Europe, Asia, the Middle East, Africa, and Latin America. Thermo Fisher forms strategic alliances to strengthen its global presence, including collaborations and partnerships.

In November 2021, Thermo Fisher Scientific Inc. partnered with CELLENION to develop workflows for single-cell, mass spectrometry-based proteomics analyses. This partnership aims to combine CELLENION's CellenOne single-cell isolation system and ProteoChip consumables with Thermo Fisher's TMT multiplexing technologies and Orbitrap mass spectrometers. Together, they will create workflows for single-cell isolation and automate sample preparation for mass spectrometry-based proteomics analysis at the single-cell level.

DANAHER CORPORATION (US):

Danaher Corporation is a leading innovator in life sciences and diagnostics, offering a wide range of products and services for medical, industrial, and commercial applications. The company has a strong presence in North America, Europe, Asia, and Latin America. Moreover, Danaher Corporation focuses on strategic alliances to enhance its global reach. In October 2023, Danaher Corporation partnered with 10X Genomics to expand automation solutions for single-cell assay workflows through its Beckman Colter Life Sciences division.

For more information, Inquire Now!

Related Reports:

Cell Isolation Market

Flow Cytometry Market

Next Generation Sequencing Market

PCR Technologies Market

Microscopy Market

Get access to the latest updates on Single Cell Analysis Companies and Single Cell Analysis Size

About MarketsandMarkets:

MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/single-cell-analysis-market-worth-us7-56-billion-by-2030-with-14-7-cagr--marketsandmarkets-302448288.html

© 2025 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.